--- title: 'Senior Director, AI and Data Science (Drug Discovery and R&D Enablement) at Lexeo Therapeutics' canonical: 'https://feeny.ai/job/senior-director-ai-and-data-science-drug-discovery-and-r-d-enablement-lexeo-wazq9qsgbtag' type: 'job' last_seen: '2026-09-14' --- # Senior Director, AI and Data Science (Drug Discovery and R&D Enablement) at Lexeo Therapeutics - **Company:** Lexeo Therapeutics - **Location:** New York, NY - **Compensation:** $230k–$332k - **Employment:** full-time - **Work type:** hybrid - **Posted:** 2026-03-19 - **Last confirmed live:** 2026-09-14 - **Apply:** https://jobs.lever.co/lexeotx/dfea0425-996a-4f48-b978-78d90c65713f ## Job description ## Role Summary Lexeo is at an inflection point where AI and advanced analytics can materially accelerate decision-making across discovery, development, and operational execution. This Sr. Director will set direction and deliver applied AI/ML solutions across internal workflows and externally facing outputs, ranging from R&D insights to partner-ready analyses, while partnering closely with scientific teams and, when needed, external vendors/partners to solve real problems. This role is intentionally hands-on and outcome-driven: a leader who can build, validate, and operationalize models using real-world biopharma data to raise the signal-to-noise ratio in small or unstructured datasets (including synthetic control arm approaches where appropriate). ## Key Responsibilities AI/ML Strategy + Delivery - Define and execute Lexeo’s applied AI/ML roadmap across discovery and development, prioritizing use cases that improve speed, quality, and decision confidence. - Deliver solutions that are internal-only (e.g., scientific decision support, operational forecasting) and those that are generated internally but external-facing (e.g., partner-ready analyses (regulatory dossiers, briefing books, protocols etc.), validated dashboards, and decision materials). - Establish best practices for model lifecycle management (validation, documentation, monitoring, retraining), especially where outputs influence scientific decisions or regulated workflows. Advanced Analytics + Predictive Modeling - Lead development and selection of appropriate ML approaches (e.g., XGBoost, Random Forest, SVMs, and other advanced models) based on problem framing, data constraints, interpretability needs, and deployment context. - Build and oversee predictive analytics using real-world data, including robust evaluation design, bias/variance trade-offs, and performance monitoring. Small Data Excellence + Synthetic Controls - Apply techniques to amplify signal-to-noise in smaller datasets (e.g., regularization, Bayesian methods, hierarchical modeling, augmentation, multimodal integration, careful feature engineering, uncertainty quantification). - Guide strategy for synthetic control arms and comparable approaches (as appropriate), ensuring methodological rigor, transparency, and fit-for-purpose use in decision-making. Drug Discovery / Translational Partnership - Translate drug discovery and translational questions into testable analytical hypotheses; partner with bench scientists to design data capture that enables strong modeling. - Serve as a bridge between scientific teams and data/engineering, ensuring solutions are scientifically credible and operationally adoptable. Cross-functional Enablement + Platform Integration - Partner with stakeholders across R&D, CMC, Clinical, Safety, and IT/Security to implement scalable data pipelines and AI-enabled workflows. - Contribute leadership to current and emerging initiatives such as AI workflow automation/database buildouts and analytics agents that leverage enterprise platforms (examples already in motion include CMC AI automation, MaxisAI clinical database/AI efforts, and AI work to ingest historical data into Dataverse/Fabric for agent-based analysis; integration work such as a Benchling AI API initiative may also be in scope depending on priorities). External Partner/Vendor Leadership - Liaise with external partners to evaluate tools, define statements of work, and deliver solutions—while ensuring knowledge transfer and sustainable internal ownership. Operational Excellence - Improve internal processes through automation and analytics, focusing on measurable impact (cycle time, error reduction, throughput, decision latency). - Establish practical governance for data quality, documentation, and fit-for-use standards aligned with the realities of biopharma environments (including where regulated practices apply). What Success Looks like (First 6-12 Months) - A prioritized AI/analytics roadmap tied to measurable R&D outcomes; clear ownership and delivery cadence. - 2–4 production-grade analytics solutions adopted by teams (internal and/or external-facing outputs as needed). - A repeatable approach for small datasets and high-noise signals; documented modeling standards and review practices. - Strong partner engagement model: vendors/partners used strategically, with internal capability building and durable outcomes. Required Skills and Qualifications - Advanced degree in a quantitative or scientific discipline (PhD strongly preferred; MS with exceptional experience considered). - 10+ years of relevant experience across applied data science/ML in life sciences/biopharma (or adjacent domain with direct drug discovery translation), including 5+ years leading teams and influencing senior stakeholders. - Deep familiarity with advanced ML methods (including XGBoost, Random Forest, SVMs) and the judgment to select and justify the right tool for the job. - Demonstrated experience building predictive models with real-world, imperfect datasets and delivering them into production or decision workflows. - Proven ability to improve processes and operationalize analytics—moving beyond prototypes to adoption. - Strong cross-functional communication: can partner with scientists, engineers, and executives; can explain model performance and limitations clearly. ## Preferred Skills and Qualifications - Direct experience in drug discovery, translational research, and/or R&D decision support (target ID/validation, MoA, biomarker strategy, preclinical data integration). - Experience with small data strategies, causality-aware thinking, and synthetic control arms or closely related methodologies. - Experience operating in regulated/quality-sensitive environments and building documentation practices that scale (particularly relevant where validation and traceability are required). - Familiarity with enterprise data platforms and modern analytics stacks (lakehouse/warehouse patterns, feature stores, MLOps, model monitoring). ## About Lexeo Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact. Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home. Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment. ## About Lexeo Therapeutics ## Company Overview - **One-liner**: Lexeo Therapeutics is a clinical-stage genetic medicine company pioneering gene therapies to treat the root causes of inherited cardiovascular diseases and APOE4-associated Alzheimer’s disease. - **Entity Type**: Public (NYSE: LXEO) – IPO in 2023 - **Headquarters**: New York, New York, United States (345 Park Avenue South, Floor 6) - **Founded**: 2018 - **Founders**: Ronald Crystal, MD (Founder & Chief Scientific Adviser) ## Core Business - **Primary industry/industries**: Biotechnology / Genetic Medicine / Gene Therapy - **Target customers**: B2B (healthcare providers, clinical research institutions, patients via healthcare systems) – focus on larger-rare and prevalent cardiovascular indications with high unmet need. - **Mission or purpose statement**: “Reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated” (from 10-K) – also “going beyond treating the symptoms of genetic disease by trying to stop its progress at its underlying cause” (from careers page). ## Products & Services - **LX2006**: Gene therapy candidate for cardiomyopathy associated with Friedreich’s Ataxia (FA). Currently in Phase 1/2 SUNRISE-FA trial; positive interim data reported in 2025/2026. Plans to initiate a registrational study (SUNRISE-FA 2) in H1 2026. - **LX2020**: Gene therapy candidate for arrhythmogenic cardiomyopathy (ACM) caused by PKP2 mutations. In Phase 1/2 HEROIC-PKP2 trial; positive interim data announced January 2026. - **Preclinical pipeline**: Additional programs targeting hypertrophic cardiomyopathy, APOE4-associated Alzheimer’s disease, and other genetically defined conditions. ## Market Standing - **Valuation/Market Cap**: $329.6 million (as of recent data from LinkedIn, 2026) - **Key Metric**: Annual revenue of $654K (pre-commercial, clinical-stage); total funding not directly disclosed but backed by IPO and institutional investors. - **Notable Investors/Partners**: Partnerships with Weill Cornell Medicine and University of California San Diego; institutional investors include those common in biotech IPOs (specific names not listed in provided sources). - **Growth Signals**: - Headcount grew 18.5% YoY to 81 employees (LinkedIn). - Positive interim clinical data for both lead programs. - FDA feedback expected Q2 2026 for registrational trial design. - Expanded pipeline into AI/Data Science for drug discovery (new Sr. Director role posted). ## Competitive Advantages - **AAVrh10 vector technology**: High transduction efficiency in myocardial cells, lower toxicity potential, and low pre-existing immunity compared to other AAV serotypes. - **Focus on larger-rare cardiovascular diseases**: Targeting conditions with high unmet need and no approved treatments, enabling a stepwise, capital-efficient development approach. - **Strong academic partnerships**: Groundbreaking research from Weill Cornell and UCSD provides foundational science and credibility. - **Full ownership**: Retains exclusive worldwide development and commercialization rights to all product candidates. ## Strategic Focus - **Late-stage clinical advancement**: Pushing LX2006 and LX2020 toward registrational trials and potential BLA submission. - **AI and data science integration**: Hiring a Senior Director of AI and Data Science to accelerate decision-making across discovery, development, and operations. - **Expanding pipeline**: Leveraging early proof-of-concept data to address larger-rare and prevalent indications beyond current lead programs. - **Manufacturing and CMC**: Scaling up AAV manufacturing processes using Sf9/baculovirus and HEK-based systems. ## Why Work Here - **Culture**: “Passion to change the arc of medicine” – a mission-driven environment focused on transformative gene therapies. - **Work model**: Hybrid – 2 days/week in the New York City office, 3 days remote (from careers page). - **Compensation & benefits**: - Competitive salaries (e.g., Director/Sr. Director Clinical Development: $247,500 – $382,000/year) - Health, dental, vision, mental health benefits - 401(K) with company match, performance bonus, company equity - Unlimited PTO, paid holidays, paid parental leave - Commuter benefits, tech stipend, stocked kitchen, in-office lunch stipend - Life and disability insurance - **Team**: Led by pioneers in gene therapy and rare disease drug development; small but growing company (81 employees) offering high impact and cross-functional ownership. - **EEO**: Committed to an exciting, diverse, and enriching work environment. ## Sources 1. [sec.gov](https://www.sec.gov/Archives/edgar/data/1907108/000119312526193939/ars_10-k_2025.pdf) – Form 10-K for FY2025 (filed March 2026) 2. [linkedin.com](https://linkedin.com/company/lexeo-therapeutics) – LinkedIn company page (employees, revenue, market cap) 3. [lexeotx.com](https://www.lexeotx.com/careers/) – Careers page (benefits, culture, hybrid policy, job postings) 4. [jobs.lever.co](https://jobs.lever.co/lexeotx) – Lever job board (open positions) 5. [lexeotx.com](https://www.lexeotx.com/team/) – Leadership team page (founder, executives) ## Other roles at Lexeo Therapeutics - [Senior Scientist, Process Development (AAV)](https://feeny.ai/job/senior-scientist-process-development-aav-lexeo-therapeutics-new-york-7apz9n3zedj0) — New York, NY - [Associate Director, Quality Systems and Compliance](https://feeny.ai/job/associate-director-quality-systems-and-compliance-lexeo-therapeutics-new-york-ygjm53j4ddfr) — New York, NY - [Vice President, Medical Affairs](https://feeny.ai/job/vice-president-medical-affairs-lexeo-therapeutics-new-york-rfht2sa2jn1x) — New York, NY - [Director/Senior Director, Clinical Development](https://feeny.ai/job/director-senior-director-clinical-development-lexeo-therapeutics-new-york-vkywdkr3hqn8) — New York, NY